Trump Signs Bipartisan FDA User Fee Package Into Law

August 18, 2017 at 7:16 PM
President Donald Trump signed Friday (Aug. 18) the FDA Reauthorization Act of 2017, a White House spokesperson tells Inside Health Policy . The legislation was praised by lawmakers on both sides of the aisle as a way to spur medical innovations and bring lower cost drugs to market. The package reauthorizes four major FDA user fee programs: the Generic Drug User Fee Amendments (GDUFA), the Biosimilar User Fee Act (BsUFA), the Prescription Drug User Fee Act (PDUFA) and the Medical...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.